This is the authors' abstract. We don't add key points for this paper.
orasidenib significantly advances LGG treatment, targeting a prevalent mutation and slowing tumor growth. Promising preclinical and clinical evidence and manageable side effects suggest its potential impact on LGG management. However, more research, including large trials, is needed to confirm its efficacy and role in treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bombino et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: